Reversible Ocular Toxicity of Oxaliplatin: A Case Report

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2019 Jul 12

PMID 31293842

Citations 4

Authors

Arish Noor

Aakash Desai

Meghana Singh

Affiliations

Soon will be listed here.

Abstract

Oxaliplatin, a platinum-based chemotherapy agent, is commonly used in the treatment of various malignancies. Common adverse effects involve neurological, hematological, gastrointestinal system, and hypersensitivity, and rarely ocular changes have also been reported. We describe the case of a 71-year-old male, who developed reversible ocular toxicity after receiving oxaliplatin for treatment for pancreatic cancer.

Citing Articles

Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review.

Sakellakis M, Spathas N, Tsaousis K, Nikitiadis E, Linardou H, Diakonis V Cureus. 2022; 14(7):e27266.

PMID: 36039252 PMC: 9403378. DOI: 10.7759/cureus.27266.

Amaurosis Fugax: A Rare Oxaliplatin-Induced Ocular Toxicity - A Report of Three Cases.

Tunio M, Phillips K, Baker P Case Rep Oncol. 2022; 15(1):133-137.

PMID: 35350803 PMC: 8921885. DOI: 10.1159/000521842.

Oxaliplatin-Associated Amaurosis Fugax.

Kubo K, Kimura N, Watanabe R, Higashino M, Tsuda M, Kato M Case Rep Oncol. 2021; 14(2):832-837.

PMID: 34248547 PMC: 8255733. DOI: 10.1159/000516271.

Transient Vision Loss - A Rare Oxaliplatin-Induced Ophthalmologic Side Effect: A Report of Two Cases.

Ah-Thiane L, Raoul J, Hiret S, Senellart H, Dumont F, Raimbourg J Case Rep Oncol. 2021; 14(1):483-486.

PMID: 33976624 PMC: 8077355. DOI: 10.1159/000514656.

References

Simpson D, Dunn C, Curran M, Goa K . Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs. 2003; 63(19):2127-56. DOI: 10.2165/00003495-200363190-00013. View

Rubbia-Brandt L, Audard V, Sartoretti P, Roth A, Brezault C, Le Charpentier M . Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004; 15(3):460-6. DOI: 10.1093/annonc/mdh095. View

Saung M, Zheng L . Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther. 2017; 39(11):2125-2134. PMC: 5705388. DOI: 10.1016/j.clinthera.2017.08.015. View

Grothey A . Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005; 5 Suppl 1:S38-46. DOI: 10.3816/ccc.2005.s.006. View

Mesquida M, Sanchez-Dalmau B, Ortiz-Perez S, Pelegrin L, Molina-Fernandez J, Figueras-Roca M . Oxaliplatin-Related Ocular Toxicity. Case Rep Oncol. 2010; 3(3):423-427. PMC: 2999736. DOI: 10.1159/000322675. View

Park S, Lin C, Krishnan A, Goldstein D, Friedlander M, Kiernan M . Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009; 132(Pt 10):2712-23. DOI: 10.1093/brain/awp219. View

Wilkes G . Therapeutic options in the management of colon cancer: 2005 update. Clin J Oncol Nurs. 2005; 9(1):31-44. DOI: 10.1188/05.CJON.31-44. View

Brandi G, Pantaleo M, Galli C, Falcone A, Antonuzzo A, Mordenti P . Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003; 89(3):477-81. PMC: 2394366. DOI: 10.1038/sj.bjc.6601155. View

Leonard G, Wright M, Quinn M, Fioravanti S, Harold N, Schuler B . Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005; 5:116. PMC: 1266024. DOI: 10.1186/1471-2407-5-116. View

10.

Grothey A, Goldberg R . A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004; 5(10):2159-70. DOI: 10.1517/14656566.5.10.2159. View

11.

ODea D, Handy C, Wexler A . Ocular changes with oxaliplatin. Clin J Oncol Nurs. 2006; 10(2):227-9. DOI: 10.1188/06.CJON.227-229. View

12.

Noguchi Y, Kawashima Y, Kawara H, Tokuyama Y, Tamura Y, Uchiyama K . [A Retrospective Analysis of Eye Disorders Due to Oxaliplatin]. Gan To Kagaku Ryoho. 2015; 42(11):1401-5. View

13.

Imperia P, Lazarus H, Lass J . Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 1989; 34(3):209-30. DOI: 10.1016/0039-6257(89)90105-7. View